Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-131 rituximab plus maintenance rituximab for advanced indolent follicular and low-grade non-Hodgkin lymphoma
ACTRN12607000153415Phase 2Recruiting
- Sponsor
- Fremantle Hospital
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iodine-131-rituximab and rituximab in follicular lymphoma (FL), mature B-cell lymphoma, Lymphoplasmacytic Lymphoma (LPL) and 3 more, sponsored by Fremantle Hospital. Primary endpoints: Overall survival and Disease-free survival. Started Feb 2007; status: recruiting.
02
Drugs
iodine-131-rituximabrituximab
03
Conditions
follicular lymphoma (FL)mature B-cell lymphomaLymphoplasmacytic Lymphoma (LPL)marginal zone B-cell lymphoma (MZL)extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on ACTRN12607000153415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000153415.